| |
CHOOSE FROM ONE OF THE FOLLOWING SESSIONS
Click the appropriate button below to register |
|
In this second of two webinars, national and international experts in AML address the latest and most important novel therapies in AML with the potential to change outcomes, including emerging triplet regimens, bispecific antibodies, CAR T-cell therapies and other non-intensive approaches.
After viewing this in-depth and critical analysis of evolving triplet regimens for FLT-3-positive AML patients, the current status and future potential of CD47-targeting agents, clinical trials of bispecific antibodies and CAR T-cell therapies and strategies for treating AML patients in the community hospital setting, participants will have the opportunity to ask questions of our experts in a live, 15-minute Q&A session.
Join us to gain an understanding not only of where treatment for AML is now, but of the evolving therapies that will fundamentally change outcomes for these complex patients in the future. |
Faculty |
Eytan M. Stein, MD
Chief, Leukemia Service
Director, Program for Drug Development
in Leukemia
Associate Attending Physician
Leukemia Service,
Department of Medicine
Memorial Sloan Kettering
Cancer Center
New York, New York
|
David Sallman, MD
Leukemia & MDS Section Head
Associate Member
Department of Malignant Hematology
H. Lee Moffitt Cancer Center
& Research Institute
Assistant Professor, Department of
Oncologic Sciences
University of South Florida
Tampa, Florida
|
Marion Subklewe, MD
Head of the Laboratory for Translational Cancer Immunotherapy
Professor of Internal Medicine
Ludwig Maximilian University
Munich, Germany
|
|
Agenda Topics
Advances in Non-Intensive Therapies for AML: From CD47-Targeting to Combination Strategies and Beyond
- Tailoring frontline combination therapies for AML patients unfit for intensive chemotherapy
- CD47 inhibition as non-intensive therapy in AML
- Bispecific and T-cell redirecting therapies in AML
- The evolving role of CAR T-cell therapies in AML
- Treating patients with AML with non-intensive therapies in the community setting
Target Audience
This activity is intended for hematologists/oncologists and other healthcare providers involved in the treatment of patients with AML.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Evaluate the emerging role of frontline combination therapies in non-intensive treatment of AML
- Summarize advances in the evolving landscape of non-intensive therapies in AML and the potential of these agents to impact clinical practice
- Outline practical strategies for incorporating non-intensive therapies for patients with AML, as each is approved
Accreditation/CE
 |
CME Credit
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MediCom Worldwide, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. |
|
Nursing Credit
MediCom Worldwide, Inc. is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 24-027-183 |
|
Disclosure
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.
Faculty Disclosures
Dr. Eytan Stein has relevant financial relationships related to formal advisory activities from and owns significant holdings in Abbvie, Inc., Agios, Inc., Astellas Pharma US, Inc., Auron Therapeutics, Bristol-Myers Squibb Company, Celgene Corporation – a Bristol-Meyers Squibb Company, Genentech, Inc., Gilead, Janssen Pharmaceuticals, Inc., Syndax Pharmaceuticals and Syros Pharmaceuticals, Inc.
Dr. David Sallman has relevant financial relationships related to formal advisory/consultant activities from Abbvie, Inc., Affimed GmbH, Astellas Pharma US, Inc., AvenCell Therapeutics, Inc., bluebird bio, Inc., Bristol-Myers Squibb Company, Dark Blue Therapeutics, Foghorn Therapeutics, Gilead, Incyte Corporation, Intellia Therapeutics, Inc., Intellisphere LLC, Jasper Therapeutics, Inc., Kite Pharma, Inc. – a Gilead Company, Magenta Therapeutics, Molecular Partners AG, Nkarta, Inc., Novartis AG, PGEN Therapeutics, Inc., Orbital Therapeutics Inc., Rigel Pharmaceuticals, Inc., Shattucks Labs, Inc., Servier, Syndax Pharmaceuticals, Syros Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited and Zentalis Pharmaceuticals, Inc.; and has received research support from Aprea Therapeutics and Jazz Pharmaceuticals, Inc.
Dr. Marion Subklewe has no relevant financial relationships to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated.
|
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.
Planning Committee
Joan Meyer, RN, MHA, Executive Director, Sheri Sturgis, Strategy and Education Manager, and Jennifer Murphy, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
Peer Reviewer
Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
Instructions for Participation and Credit
There are no fees for participating in this activity.
In order to receive credit, all participants must complete the post-test and activity evaluation following the activity. Partial credit will not be awarded for this activity.
CME, CNE, and CE Credit certificates will be emailed 4 weeks following receipt of completed requirements.
If you have any questions regarding the content of this activity, please contact MediCom Worldwide, Inc. at 800-408-4242 or [email protected] |
|
|
| Provided by |
 |
This activity is supported by an educational grant from Pfizer, Inc. |
|
|
|
|
